EUCTR2020-002517-18-FR进行中（未招募）1 期
Phase II study evaluating the benefit of sequential treatment with Gemcitabine/Nab-Paclitaxel (Gembrax) then Folfirinox followed by adaptative MRI-guided stereotactic radiotherapy in patients with locally advanced adenocarcinoma of the pancreas - GABRINOX-ART
Institut régional du cancer de Montpellier (ICM)0 个研究点目标入组 103 人开始时间: 2020年7月22日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 103
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1.Patient between 18 and 75 years of age on the date of signing the consent form.
- •2.Histologically or cytologically proven pancreatic adenocarcinoma.
- •3.Eastern Cooperative Oncology Group (ECOG) performance status = 1.
- •4.Non-resecurability criteria, according to NCCN 1.2015 recommendations validated during the centralized proofreading.
- •5.Non-metastatic patient confirmed by TAP scan and hepatic MRI.
- •6.Feasibility of MRI-guided radiotherapy confirmed by central review.
- •7.Uracilemia < 16 ng/ml.
- •8.Hematologic workup obtained within 14 days prior to inclusion defined by:
- •-Neutrophils = 1 500/mm3 (1.5 × 109/L);
- •-Platelets = 100,000/mm3 (100 × 109/L);
- •-Haemoglobin = 9 g/dl
- •9.Liver function (obtained within 14 days prior to inclusion) defined by :
- •-AST and ALT = 2.5 x Upper Limit of the Standard (ULN);
- •-Total bilirubin = 1.5 x ULN; Patients with a metallic biliary prosthesis due to biliary obstruction from cancer may be included provided that a CT scan with contrast injection and fine cuts to the pancreas has been performed prior to the insertion of the biliary prosthesis, the bilirubin level after insertion of the prosthesis decreases to = 20 mg/L (= 34 µmol/l), and in the absence of angiocholitis.
- •10.Creatinine within the limits of the norm or calculated clearance = 50ml/min for patients with a creatinine value above or below the values of the norm (clearance calculated by the CKD-EPI formula).
- •11.Calcaemia = LIN and = 1.2 x ULN; magnesia = LIN and = 1.2 x ULN; kalaemia = LIN and = 1.2 x ULN.
- •12.CA 19.9 < 190 IU/mL (no icteric cholestasis). If CA 19.9 between 190 IU/mL and 500 IU/mL, the patient may be included if PET scan and peritoneal MRI do not reveal any distant metastasis indicating metastasis. If CA 19.9 = 500 IU/ML the patient is non-included.
- •13.If the patient is sexually active, the patient must agree to use contraception deemed adequate and appropriate by the investigator during the entire period of study drug administration and up to 3 months after discontinuation of treatment. In addition, male and female patients should use a method of contraception after the end of treatment as recommended in the Summary of Product Characteristics or the prescribing information for the product provided in the study manual.
- •14.Signature of consent prior to any study-specific procedure.
- •15.Affiliated with a French health insurance plan.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Any previous treatment for pancreatic cancer (chemotherapy, radiation therapy, surgery, targeted therapy or experimental therapy...)
- •2.Gilbert's syndrome known or homozygous for UGT1A1*28 validated
- •3.Other concomitant cancer or a history of cancer, with the exception of treated cervical cancer in situ, basal cell or squamous cell skin carcinoma, superficial bladder tumour (Ta, Tis, and T1) or a good prognosis tumour treated curatively without chemotherapy and without evidence of disease within 3 years prior to inclusion.
- •4.History of radiotherapy with predictable overlap with the radiotherapy treatment under study (history of abdominal irradiation).
- •5.Patients with high cardiovascular risk, including, but not limited to, coronary stent or myocardial infarction within the last 6 months.
- •6.Peripheral neuropathy = grade 2.
- •7.ECG with a QTc interval greater than 450 ms for males and greater than 470 ms for females.
- •8.Contraindication to MRI and MRI-guided radiation therapy.
- •9.History of chronic inflammatory disease of the colon or rectum.
- •10.Any other serious concomitant uncontrolled disease or disorder that may interfere with the patient's participation in the study and safety during the study (e.g., severe liver, kidney, lung, metabolic, or psychiatric disorders).
- •11.Intolerance or allergy to one of the study drugs (gemcitabine, Abraxane®, oxaliplatin, irinotecan, 5-FU) or to an excipient of one of the drugs (example: fructose) described in the Contraindications or Warnings and Special Precautions sections of the SPC or Prescribing Information.
- •12.Legal incapacity (patient under curatorship or guardianship).
- •13.Pregnant or breastfeeding woman. If a patient is of childbearing age, she must have a negative pregnancy test (serum ß-hCG) documented 72 hours prior to inclusion.
- •14.Patients using VKA (Coumadin...) (possible modification of treatment before inclusion).
- •15.Uncontrolled active bacterial or viral or fungal infection requiring systemic treatment.
- •16.Previous or known HIV infection.
- •17.History of peripheral arterial disease (e.g., claudication, Leo Buerger's disease).
- •18.Patient who received live attenuated vaccine within 10 days prior to inclusion.
- •19.Patients with a history of pulmonary fibrosis or interstitial pneumonia.
- •20.Inability to undergo medical follow-up of the trial for geographical, social or psychological reasons.
- •21.Participation in another clinical study with an investigational product within the last 30 days prior to inclusion.
研究者
相似试验
进行中（未招募）
1 期
Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic CancerCTIS2024-515344-23-00Institut Regional Du Cancer De Montpellier103
已完成
不适用
Phase II Randomized Comparative Study of Sequential Alternating Therapy with Interferon and Molecular-Targeted Drug for Advanced Renal Cell CarcinomaAdvanced Renal Cell CarcinomaJPRN-UMIN000001994Osaka Urological Oncology Research Group100
进行中（未招募）
不适用
Prospective, monocentre phase I study of sequential infusion of Y90-labeled microspheres and Mitomycine C in patients with chemorefractory liver metastases from breast carcinomaEUCTR2012-000454-58-BEniversity Hospitals Leuven
进行中（未招募）
1 期
A randomized, phase II study comparing the sequences of regorafenib and trifluridine/tipiracil, after failure of standard therapies in patients with metastatic colorectal cancerEUCTR2019-004196-39-FRICANCER340
招募中
2 期
A Phase II Study to Investigate the Efficacy and Safety of Oral intake of Anamorelin in Patients After Total GastrectomyAfter Total GastrectomyJPRN-jRCTs041230012Bando Etsuro65